DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

Angeliq (Estradiol / Drospirenone) - Published Studies

 
 



Angeliq Related Published Studies

Well-designed clinical trials related to Angeliq (Estradiol / Drospirenone)

Estradiol 1 mg and drospirenone 2 mg as hormone replacement therapy in postmenopausal Chinese women. [2011.08]

[Evaluation the efficacy and safety of estradiol and drospirenone tablets in the treatment of menopausal symptoms among postmenopausal Chinese healthy women:a randomized, multi-center, double-blind, placebo-controlled clinical study]. [2011.05]

Effects of estradiol-drospirenone hormone treatment on carotid artery intima-media thickness and vertigo/dizziness in postmenopausal women. [2011.05]

[Evaluation the efficacy and safety of estradiol and drospirenone tablets in the treatment of menopausal symptoms among postmenopausal Chinese healthy women:a randomized, multi-center, double-blind, placebo-controlled clinical study]. [Article in Chinese] [2011]

Angeliq versus Activelle in normotensive postmenopausal women: a prospective, randomized pilot study. [2009.07]

Comparison of the effects of hormone therapy regimens, oral and vaginal estradiol, estradiol + drospirenone and tibolone, on sexual function in healthy postmenopausal women. [2008.01]

Effect of estradiol-drospirenone hormone treatment on myocardial perfusion reserve in postmenopausal women with angina pectoris. [2007.06.15]

Efficacy of a new oral contraceptive containing drospirenone and ethinyl estradiol in the long-term treatment of hirsutism. [2006.02]

Well-designed clinical trials possibly related to Angeliq (Estradiol / Drospirenone)

Low-dose estrogen and drospirenone combination: effects on glycoinsulinemic metabolism and other cardiovascular risk factors in healthy postmenopausal women. [2011.01]

Other research related to Angeliq (Estradiol / Drospirenone)

Effects of estradiol-drospirenone on ocular and nasal functions in postmenopausal women. [2011.08]

Effects of estradiol-drospirenone hormone treatment on carotid artery intima-media thickness and vertigo/dizziness in postmenopausal women. [2011]

Effects of estradiol-drospirenone hormone treatment on carotid artery intima-media thickness and vertigo/dizziness in postmenopausal women. [2010.05.05]

Angeliq versus Activelle in normotensive postmenopausal women: a prospective, randomized pilot study. [2009.02.03]

Characteristics of nasal epithelial cells in naturally postmenopausal women receiving hormone therapy with 1 mg 17beta-estradiol and 2 mg drospirenone: a prospective study. [2008.09]

The concomitant prescribing of ethinyl estradiol/drospirenone and potentially interacting drugs. [2007.10]

Coadministration of estradiol/drospirenone and indomethacin does not cause hyperkalemia in healthy postmenopausal women: a randomized open-label crossover study. [2007.06]

Coadministration of Estradiol/Drospirenone and Indomethacin Does Not Cause Hyperkalemia in Healthy Postmenopausal Women: A Randomized Open-Label Crossover Study. [2007.04.26]

Drospirenone with 17beta-estradiol in the postmenopausal woman with hypertension. [2007.02]

Drospirenone and estradiol: a new option for the postmenopausal woman. [2007.02]

Serum potassium monitoring for users of ethinyl estradiol/drospirenone taking medications predisposing to hyperkalemia: physician compliance and survey of knowledge and attitudes. [2007.02]

[Medication of the month. Angeliq: new hormonal therapy of menopause, with antialdosterone and antiandrogenic properties] [2004.03]

Other possibly related research studies

Effects of blood pressure reduction on cardiovascular risk estimates in hypertensive postmenopausal women. [2007.02]

Advances in hormone replacement therapy with drospirenone, a unique progestogen with aldosterone receptor antagonism. [2006.11.20]

Added benefits of drospirenone for compliance. [2005.10]

Drospirenone in combination with estrogens: for contraception and hormone replacement therapy. [2005.10]

Supplementary data collection with case-cohort analysis to address potential confounding in a cohort study of thromboembolism in oral contraceptive initiators matched on claims-based propensity scores. [2008.03]

[The impact of a new low dose oral contraceptive containing drospirenone on lipid profile, carbohydrate metabolism and hepatic function] [2009.02]

[The influence of a combined low dose oral contraceptive containing drospirenone on electrolite equlibrum and renal function in young woman] [2009.01]

[A young woman with cardiac arrest] [2010.01.14]

Low-dose estrogen and drospirenone combination: effects on glycoinsulinemic metabolism and other cardiovascular risk factors in healthy postmenopausal women. [2011]

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2014